RA Capital Healthcare Fund trims Vor Biopharma (NASDAQ: VOR) stake, still holds 3.9M shares

Rhea-AI Filing Summary

RA Capital Healthcare Fund LP, an entity associated with RA Capital Management, reported open-market sales of Vor Biopharma common stock over three days. The filings show indirect sales totaling 620,133 shares of Common Stock on April 8–10, 2026, at weighted average prices between $15.75 and $16.98 per share, executed in multiple trades within those ranges. After these transactions, the reporting group indicates indirect ownership of 3,935,608 shares. The Adviser, its general partner, the Fund, and individuals Peter Kolchinsky and Rajeev Shah each disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest.

Insights

Insider transactions analyst

RA Capital-linked fund sold 620k Vor Biopharma shares but retains a multi‑million share stake.

The data show four open-market sales of Vor Biopharma common stock by RA Capital Healthcare Fund LP, reported as indirect holdings of RA Capital Management entities. Across April 8–10, 2026, the fund sold a combined 620,133 shares at prices in the mid‑$15 to high‑$16 range.

All transactions are coded as sales (S) with no option exercises or grants, so this is straightforward profit‑taking or portfolio rebalancing based on the information provided. After the sales, the reporting group still holds 3,935,608 shares indirectly, indicating a continuing, sizeable position rather than a full exit.

Footnotes clarify that shares are held directly by the Fund and that RA Capital Management, its general partner, and principals Peter Kolchinsky and Rajeev Shah disclaim beneficial ownership beyond their pecuniary interests. The filing does not reference any pre‑arranged trading plan, so timing context is not provided in the excerpt.

Insider Trade Summary

Net Seller: 620,133 shares ($10,233,811)

Net Sell 4 txns

Insider RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M.

Role Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner

Sold 620,133 shs ($10.23M)

Type	Security	Shares	Price	Value
Sale	Common Stock	828	$15.75	$13K
Sale	Common Stock	135,201	$16.59	$2.24M
Sale	Common Stock	353,242	$16.32	$5.76M
Sale	Common Stock	130,862	$16.91	$2.21M

Holdings After Transaction: Common Stock — 3,935,608 shares (Indirect, See footnotes)

Footnotes (1)

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.755 to $16.68 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. Held directly by the Fund. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.755 to $16.975 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.94 to $16.385 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.75 to $15.76 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Total shares sold: 620,133 shares Shares sold on April 8, 2026 (block 1): 353,242 shares Shares sold on April 8, 2026 (block 2): 130,862 shares +4 more

7 metrics

Total shares sold 620,133 shares Net open-market sales on April 8–10, 2026

Shares sold on April 8, 2026 (block 1) 353,242 shares Common Stock sale at $16.32 per share

Shares sold on April 8, 2026 (block 2) 130,862 shares Common Stock sale at $16.91 per share

Shares sold on April 9, 2026 135,201 shares Common Stock sale at $16.59 per share

Shares sold on April 10, 2026 828 shares Common Stock sale at $15.75 per share

Shares owned after trades 3,935,608 shares Indirect ownership following April 10, 2026 sales

Number of sale transactions 4 transactions All coded as open-market sales (S)

Key Terms

weighted average price, beneficial ownership, pecuniary interest, indirect ownership, +1 more

5 terms

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

beneficial ownership financial

"disclaims beneficial ownership of any of the reported securities"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

pecuniary interest financial

"disclaims beneficial ownership ... except to the extent of its or his respective pecuniary interest"

indirect ownership financial

"total_shares_following_transaction ... ownership_type: "indirect""

open-market sale financial

"transaction_action: "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RA CAPITAL MANAGEMENT, L.P.

(Last) (First) (Middle)

200 BERKELEY STREET 18TH FLOOR

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Vor Biopharma Inc. [ VOR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/08/2026		S		353,242	D	$16.32(1)	4,202,499	I	See footnotes(2)(3)
Common Stock	04/08/2026		S		130,862	D	$16.91(4)	4,071,637	I	See footnotes(2)(3)
Common Stock	04/09/2026		S		135,201	D	$16.59(5)	3,936,436	I	See footnotes(2)(3)
Common Stock	04/10/2026		S		828	D	$15.75(6)	3,935,608	I	See footnotes(2)(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

RA CAPITAL MANAGEMENT, L.P.

(Last) (First) (Middle)

200 BERKELEY STREET 18TH FLOOR

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

RA Capital Healthcare Fund LP

(Last) (First) (Middle)

200 BERKELEY STREET, 18TH FLOOR

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Kolchinsky Peter

(Last) (First) (Middle)

C/O RA CAPITAL MANAGEMENT, L.P.

200 BERKELEY STREET, 18TH FLOOR

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Shah Rajeev M.

(Last) (First) (Middle)

C/O RA CAPITAL MANAGEMENT, L.P.

200 BERKELEY STREET, 18TH FLOOR

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.755 to $16.68 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

2. RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.

3. Held directly by the Fund.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.755 to $16.975 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.94 to $16.385 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.75 to $15.76 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

Dr. Andrew Levin, a Partner and Managing Director of the Adviser, serves on the Issuer's board of directors.

	/s/ Peter Kolchinsky, Manager of RA Capital Management, L.P.	04/10/2026
	/s/ Peter Kolchinsky, Manager of RA Capital Healthcare GP, LLC, the General Partner of RA Capital Healthcare Fund, L.P.	04/10/2026
	/s/ Peter Kolchinsky, individually	04/10/2026
	/s/ Rajeev Shah, individually	04/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

How many Vor Biopharma (VOR) shares did RA Capital-related entities sell?

They reported open-market sales totaling 620,133 Vor Biopharma shares. These transactions occurred over three days and are all coded as sales of common stock, reducing but not eliminating their indirect ownership position in the company.

Over what dates did RA Capital Healthcare Fund trade Vor Biopharma (VOR) stock?

The filing shows sales on April 8, 9, and 10, 2026. Each date includes open-market transactions in Vor Biopharma common stock, with weighted average sale prices disclosed in the mid‑$15 to high‑$16 range.

What is RA Capital’s remaining indirect Vor Biopharma (VOR) stake after these Form 4 sales?

After the reported sales, the filing lists 3,935,608 Vor Biopharma shares as indirectly owned. This indicates that, despite selling 620,133 shares, the RA Capital-associated fund continues to hold a large multi‑million share position.

At what prices did RA Capital’s fund sell Vor Biopharma (VOR) shares?

The reported weighted average prices range from about $15.75 to $16.98 per share. Footnotes explain that each day’s figure reflects multiple trades within specified price bands and that detailed trade breakdowns are available upon request.

Who is attributed as the seller in this Vor Biopharma (VOR) Form 4?

The shares are held directly by RA Capital Healthcare Fund LP. RA Capital Management, its general partner, and principals Peter Kolchinsky and Rajeev Shah report indirect ownership but disclaim beneficial ownership beyond their respective pecuniary interests.